AstraZeneca (AZN) Enters Brodalumab Licensing Agreement with Valeant (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of Synergetics USA (SURG)
September 2, 2015 10:23 AM EDTBMO Capital reiterated an Outperform rating and $285.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announced agreement to buy Synergetics USA (NASDAQ: SURG). Analyst Alex Arfaei said that although this is a small... More
Valeant picks up AstraZeneca psoriasis drug after Amgen exit
September 1, 2015 2:31 AM EDT(Reuters) - Canada's Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) is buying rights to AstraZeneca Plc's (NYSE: AZN) late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc (NASDAQ: AMGN) in... More
FDA Issues Warning on DPP-4 Inhibitors in T2D (MRK) (LLY)
August 28, 2015 12:36 PM EDTThe U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. We have added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors.
Patients should not stop taking their DPP-4 inhibitor medicine, but should contact their health care professional right... More
